RAX2

Across TCGA pan-cancer cohorts, RAX2 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated RAX2 data layer.

The strongest signal is observed in small cell lung cancer (SCLC), where higher RAX2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated RAX2 expression acts as an unfavorable survival marker, although some lineages such as SCLC and BRCA show a favorable association.

SCLC, THCA, and DLBC are the cancer types where RAX2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Tertile	All	0.763	0.473	<.001	108	view →
THCA	DFS	Tertile	II,III,IV	0.200	0.853	<.001	80	view →
DLBC	DFS	Tertile	III,IV	0.071	0.764	.004	55	view →
ACC	OS	Tertile	All	0.587	0.924	<.001	45	view →
BRCA	DFS	Tertile	II,III,IV	0.690	0.434	<.001	44	view →
MESO	OS	Median	All	0.735	0.289	.004	42	view →
KIRC	DFS	Quartile	III,IV	0.239	0.463	.002	32	view →
UVM	DFS	Quartile	All	0.318	0.870	.001	31	view →
STAD	DFS	Tertile	IV	0.088	0.456	.009	28	view →
ESCA	DFS	Quartile	II,III,IV	0.507	0.302	.021	24	view →
LUSC	OS	Tertile	All	0.518	0.361	.015	18	view →
LAML	DFS	Tertile	All	0.563	0.233	.007	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

RAX2–SCLC (DFS)

Open the SCLC breakdown →